Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Epilepsia. 2023 Oct;64(10):2625-2634. doi: 10.1111/epi.17716. Epub 2023 Jul 25.
This study was undertaken to evaluate how the challenges in the recruitment and retention of participants in clinical trials for focal onset epilepsy have changed over time.
In this systematic analysis of randomized clinical trials of adjunct antiseizure medications for medication-resistant focal onset epilepsy, we evaluated how the numbers of participants, sites, and countries have changed since the first such trial in 1990. We also evaluated the proportion of participants who completed each trial phase and their reasons for early trial exit. We analyzed these trends using mixed effects generalized linear models accounting for the influence of the number of trial sites and trial-specific variability.
The number of participants per site has steadily decreased over decades, with recent trials recruiting fewer than five participants per site (reduction by .16 participants/site/year, p < .0001). Fewer participants also progressed from recruitment to randomization over time (odds ratio = .94/year, p = .014). Concurrently, there has been an increase in the placebo response over time (increase in median percent reduction of .4%/year, p = .02; odds ratio of increase in 50% responder rate of 1.03/year, p = .02), which was not directly associated with the number of sites per trial (p > .20).
This historical analysis highlights the increasing challenges with participant recruitment and retention, as well as increasing placebo response. It serves as a call to action to change clinical trial design to address these challenges.
本研究旨在评估随着时间的推移,局灶性癫痫发作临床试验中参与者招募和保留所面临的挑战发生了怎样的变化。
在这项针对药物难治性局灶性癫痫发作辅助抗癫痫药物的随机临床试验的系统分析中,我们评估了自 1990 年首例此类试验以来,参与者人数、试验地点和国家数量的变化情况。我们还评估了每个试验阶段完成的参与者比例及其提前退出试验的原因。我们使用混合效应广义线性模型分析了这些趋势,该模型考虑了试验地点数量和试验特异性变异性的影响。
每个试验点的参与者人数在几十年中稳步下降,最近的试验每个试验点的参与者人数不到 5 人(每年减少.16 名参与者/试验点,p<0.0001)。随着时间的推移,从招募到随机分组的参与者也越来越少(比值比=0.94/年,p=0.014)。同时,随着时间的推移,安慰剂效应也在增加(中位数百分比降低增加.4%/年,p=0.02;50%应答率增加的优势比为 1.03/年,p=0.02),但这与每个试验的试验点数量没有直接关联(p>0.20)。
这项历史分析强调了参与者招募和保留方面的挑战不断增加,以及安慰剂效应的增加。它呼吁改变临床试验设计,以应对这些挑战。